Neuropace Inc - Asset Resilience Ratio
Neuropace Inc (NPCE) has an Asset Resilience Ratio of 40.38% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Neuropace Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Neuropace Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Neuropace Inc (NPCE) total assets.
Liquid Assets Composition Over Time
This chart breaks down Neuropace Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read NPCE total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $39.16 Million | 40.38% |
| Total Liquid Assets | $39.16 Million | 40.38% |
Asset Resilience Insights
- Very High Liquidity: Neuropace Inc maintains exceptional liquid asset reserves at 40.38% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Neuropace Inc Industry Peers by Asset Resilience Ratio
Compare Neuropace Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic plc
SA:MDTC34 |
Medical Devices | 7.82% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Biosynex
PA:ALBIO |
Medical Devices | 3.35% |
Annual Asset Resilience Ratio for Neuropace Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Neuropace Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.29% | $39.37 Million | $105.56 Million | -4.26pp |
| 2024-12-31 | 41.55% | $39.33 Million | $94.65 Million | -3.41pp |
| 2023-12-31 | 44.96% | $48.40 Million | $107.65 Million | -17.09pp |
| 2022-12-31 | 62.05% | $70.80 Million | $114.11 Million | -10.12pp |
| 2021-12-31 | 72.17% | $96.40 Million | $133.56 Million | +51.28pp |
| 2020-12-31 | 20.89% | $11.69 Million | $55.95 Million | +16.30pp |
| 2019-12-31 | 4.59% | $969.00K | $21.09 Million | -- |
About Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable a… Read more